Drugs Information:
Inotersen
Basic Information
|
||
| ID | DDInter926 | |
| Drug Type | biotech | |
| Protein Chemical Formula | C230H318N69O121P19S19 | |
| Protein Average Weight | 7183.077 | |
| CAS Number | 1492984-65-2 | |
| Description | Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It was FDA approved in October 2018.[L11761] Inotersen has been shown to improve the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis [A39493]. Hereditary transthyretin amyloidosis is caused by single-nucleotide variants in the gene encoding transthyretin (TTR), which lead to transthyretin misfolding and the deposition of amyloid substance systemically. Progressive amyloid accumulation may lead to multiorgan dysfunction and death [A39493]. | |
| ATC Classification | N07XX15 | |
| Sequences | None | |
| Useful Links | DrugBank Wikipedia | |
Interactions with
Inotersen
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|